VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
EG
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
EGEverest Re Group, Ltd.
$355.52$14.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksEGFinancials

Everest Re Group, Ltd. (EG) Financials

30Y historyFree accessUpdated daily

Revenue growth has stagnated with a 4.0% contraction in 2026Q1, while underwriting profitability remains sensitive to loss events, evidenced by combined ratios fluctuating between 79.6% and 116.1% over the last ten quarters.

EG Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue17.15B17.32B17.08B14.46B11.98B11.33B9.6B8.23B7.36B6.62B5.79B5.68B5.68B5.64B4.92B4.69B4.71B4.5B3.53B4.78B4.52B4.56B5.02B4.11B2.56B1.8B1.48B2.61B1.32B1.3B1.17B
Revenue Growth %-0.49%1.42%18.06%20.68%5.8%18.02%16.61%11.81%11.16%14.29%2.07%-0.04%0.68%14.59%4.88%-0.25%4.61%27.53%-26.23%5.86%-0.99%-9.07%22.16%60.58%41.97%21.74%-43.4%98.78%1.23%11.11%-
Medical Costs & Claims12.26B13.76B14.61B11.38B10.63B9.6B8.42B6.63B7.17B5.83B4.33B4.25B4B3.78B3.7B4.68B3.88B2.37B2.44B2.7B2.57B3.85B3.41B2.69B2.25B1.27B936.25M819.83M827.97M326.5M56.5M
Medical Cost Ratio %71.52%79.48%85.53%78.67%88.68%84.75%87.77%80.51%97.4%87.98%74.7%74.84%70.38%66.97%75.12%99.63%82.4%52.77%69.14%56.48%56.95%84.47%67.88%65.61%88.01%70.41%63.27%31.36%62.95%25.13%4.83%
Gross Profit4.88B3.55B2.47B3.08B1.36B1.73B1.17B1.6B191.06M795.75M1.47B1.43B1.68B1.86B1.22B17.24M828.24M2.12B1.09B2.08B1.94B708.34M1.61B1.41B306.62M533.14M543.58M1.79B487.24M972.7M1.11B
Gross Margin %28.48%20.52%14.47%21.33%11.32%15.25%12.23%19.49%2.6%12.02%25.3%25.16%29.62%33.03%24.88%0.37%17.6%47.23%30.86%43.52%43.05%15.53%32.12%34.39%11.99%29.59%36.73%68.64%37.05%74.87%95.17%
Gross Profit Growth %-43.82%-19.9%127.34%-21.47%47.19%-26.83%739.8%-75.99%-45.72%2.63%-15.07%-9.72%52.1%7006.31%-97.92%-61.02%95.16%-47.7%7.01%174.57%-56.04%14.09%360.65%-42.49%-1.92%-69.71%268.31%-49.91%-12.59%-
Operating Expenses2.44B1.6B976M931M769M184M588M505.56M433.24M376.34M366.18M316.51M295.06M308.06M285.32M251.18M237M1.19B1.17B1.05B953.15M989.26M1.05B921.22M44.57M442.8M311.83M1.6B274.56M00
OpEx / Revenue %14.24%9.24%5.72%6.44%6.42%1.62%6.13%6.14%5.89%5.68%6.32%5.58%5.2%5.46%5.8%5.35%5.04%26.35%33.23%22.03%21.1%21.68%20.96%22.43%1.74%24.58%21.07%61.12%20.88%0%0%
Depreciation & Amortization0000000000000000000-8.43M21.95M27.46M24.92M10.64M-7.34M152K112K0000
Combined Ratio %85.77%88.72%91.25%85.11%95.09%86.37%93.89%86.65%103.29%93.67%81.02%80.41%75.58%72.43%80.91%104.98%87.44%79.12%102.37%78.5%78.05%106.16%88.85%88.04%89.75%94.99%84.34%92.48%83.83%25.13%4.83%
Operating Income2.44B1.95B1.5B2.15B588M1.54B586M1.1B-242.18M419.41M1.1B1.11B1.39B1.55B939.53M-233.95M591.24M939.32M-83.61M1.03B991.75M-280.92M559.7M491.21M262.04M90.34M231.74M196.58M212.68M972.7M1.11B
Operating Margin %14.23%11.28%8.75%14.89%4.91%13.63%6.11%13.35%-3.29%6.33%18.98%19.59%24.42%27.57%19.09%-4.98%12.56%20.88%-2.37%21.5%21.95%-6.16%11.15%11.96%10.25%5.01%15.66%7.52%16.17%74.87%95.17%
Operating Income Growth %-30.7%-30.59%266.33%-61.92%163.48%-46.68%553.79%-157.74%-61.87%-1.08%-19.82%-10.81%65.51%501.6%-139.57%-37.06%1223.5%-108.13%3.65%453.04%-150.19%13.94%87.45%190.05%-61.02%17.89%-7.57%-78.14%-12.59%-
EBITDA2.52B2.07B1.64B2.29B689M1.62B621M1.13B-211.15M451.01M1.14B1.15B1.43B1.6B993.21M-181.63M647.07M1.01B-4.44M1.02B1.01B-253.46M584.62M501.85M254.71M90.5M231.85M198.07M212.68M972.7M1.11B
EBITDA Margin %14.68%11.94%9.62%15.82%5.75%14.27%6.47%13.74%-2.87%6.81%19.61%20.22%25.1%28.38%20.18%-3.87%13.75%22.48%-0.13%21.32%22.44%-5.56%11.65%12.22%9.96%5.02%15.67%7.58%16.17%74.87%95.17%
Interest Expense137M139M149M134M101M70M36M31.69M31.03M31.6M36.23M36.19M38.53M46.12M53.68M52.32M55.83M72.08M79.17M91.56M68.6M72.96M75.54M57.29M44.57M46M39.39M1.49M000
Non-Operating Income-77M-114M-147M-134M-101M-72M-35M-31.69M-31.03M-31.6M-36.23M-36.19M-38.53M-46.12M-53.68M-52.32M-55.83M-72.08M-79.17M-91.56M-68.6M-72.96M-75.54M-57.29M-44.57M-46M-39.39M-1.49M000
Pretax Income2.42B1.93B1.49B2.15B588M1.55B585M1.1B-242.18M419.41M1.1B1.11B1.39B1.55B939.53M-233.95M591.24M939.32M-83.61M1.03B991.75M-280.92M559.7M491.21M262.04M90.34M231.74M196.58M212.68M207.3M143.8M
Pretax Margin %14.09%11.14%8.74%14.89%4.91%13.65%6.1%13.35%-3.29%6.33%18.98%19.59%24.42%27.57%19.09%-4.98%12.56%20.88%-2.37%21.5%21.95%-6.16%11.15%11.96%10.25%5.01%15.66%7.52%16.17%15.96%12.3%
Income Tax383M339M120M-363M-9M167M71M89.53M-331.22M-63.34M103.5M134.02M187.65M289.71M110.57M-153.46M-19.52M132.33M-64.85M188.68M150.92M-62.25M64.9M65.19M30.74M-8.68M45.36M38.52M47.48M52.3M31.8M
Effective Tax Rate %15.85%17.57%8.04%-16.85%-1.53%10.8%12.14%8.15%136.77%-15.1%9.41%12.05%13.53%18.63%11.77%65.6%-3.3%14.09%77.56%18.35%15.22%22.16%11.6%13.27%11.73%-9.6%19.57%19.6%22.32%25.23%22.11%
Net Income2.03B1.59B1.37B2.52B597M1.38B514M1.01B89.04M482.75M996.34M977.87M1.2B1.26B828.95M-80.49M610.75M806.99M-18.76M839.27M840.83M-218.67M494.9M426.03M231.3M99.02M186.38M158.06M165.2M155M112M
Net Margin %11.86%9.19%8.04%17.4%4.98%12.17%5.36%12.26%1.21%7.29%17.2%17.23%21.12%22.33%16.84%-1.71%12.98%17.94%-0.53%17.55%18.61%-4.79%9.86%10.37%9.04%5.5%12.59%6.05%12.56%11.93%9.58%
Net Income Growth %139.29%15.88%-45.45%321.61%-56.71%168.29%-49.08%1033.7%-81.56%-51.55%1.89%-18.45%-4.78%51.92%1129.94%-113.18%-24.32%4402.11%-102.24%-0.18%484.52%-144.18%16.17%84.19%133.6%-46.87%17.92%-4.32%6.58%38.39%-
EPS (Diluted)50.4937.8631.7860.2415.1934.6212.7824.702.5311.3623.6822.1025.9125.4415.79-1.4910.7013.22-0.3013.1912.87-3.798.717.744.522.104.023.258.147.976.07
EPS Growth %150.87%19.13%-47.24%296.58%-56.12%170.89%-48.26%876.28%-77.73%-52.03%7.15%-14.7%1.85%61.11%1159.73%-113.93%-19.06%4506.67%-102.27%2.49%439.58%-143.51%12.53%71.24%115.24%-47.76%23.69%-60.07%2.13%31.3%-
EPS (Basic)-37.8631.7860.1915.1934.6612.8124.772.5411.4323.8522.2926.1625.6715.85-1.4910.7313.26-0.3013.3012.99-3.798.857.894.602.144.063.268.198.016.10
Diluted Shares Outstanding40.28M41.41M42.7M41.3M39M39.3M39.73M40.42M40.93M41.28M42.08M44.25M46.28M49.5M52.5M54.02M57.08M61.04M61.67M63.63M65.32M57.65M56.82M55.01M51.14M47.11M46.36M48.69M50.66M50.77M50.68M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Catastrophe loss volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Top Line Growth Remains Stagnant

As reported in recent financial statements, Everest Group's revenue growth has decelerated significantly, with the most recent quarter showing a 4.0% contraction, suggesting that the firm is prioritizing underwriting discipline and margin preservation over aggressive premium volume expansion in the current competitive global reinsurance market environment.

The shift from double-digit growth in early 2024 to negative territory in 2026 suggests a strategic pivot toward more selective risk assumption. Investors should monitor whether this contraction reflects a deliberate retreat from softening market segments or an inability to maintain lead positions in key renewal cycles.

Underwriting Profitability Shows Cyclical Sensitivity

Based on the company's reported figures, the combined ratio has fluctuated between 79.6% and 116.1% over the last ten quarters, indicating that underwriting profitability remains highly sensitive to catastrophe events and the inherent volatility of the firm's diversified reinsurance and primary insurance business model.

The sharp deterioration in the 2024Q4 combined ratio to 116.1% highlights the vulnerability of the current portfolio to large-scale loss events. While the subsequent recovery to 81.9% in 2026Q1 suggests effective remediation, the volatility in the loss ratio warrants further investigation into the adequacy of current pricing models.

2024Q4 Loss Event Impact Analysis

According to the provided quarterly data, the 2024Q4 period represents a critical inflection point where the company recorded a net loss of $593 million, driven by a 110% loss ratio that severely impacted the firm's operating income and overall profitability trajectory for the subsequent fiscal year.

This period serves as a stark reminder of the earnings volatility inherent in the reinsurance sector. The subsequent rebound in operating income suggests that the company possesses the capital flexibility to absorb significant shocks, though it raises questions regarding the consistency of future earnings power.

Casualty Exposure Risks Future Earnings

While the firm has successfully diversified into primary insurance, the increasing exposure to casualty and specialty lines, as noted in recent company intelligence, may introduce long-tail litigation risks that could mask underlying underwriting issues through delayed reserve development and potential future adverse loss experience.

The transition toward casualty lines may offer lower volatility than property catastrophe, but it shifts the risk profile toward social inflation and legal environment changes. Investors should remain cautious, as these liabilities are often harder to quantify and may not manifest in the combined ratio until several years post-inception.

EG — Frequently Asked Questions

Quick answers to the most common questions about buying EG stock.

What was Everest Re Group, Ltd.'s (EG) revenue in 2025?

For fiscal year 2025, Everest Re Group, Ltd. (EG) reported total revenue of $17.32B. This represents a 1381.1% increase compared to $1.17B in 1996.

Is Everest Re Group, Ltd. (EG) profitable?

Everest Re Group, Ltd. (EG) is profitable, generating $1.59B in net income for the fiscal year ending 2025 with a net profit margin of 9.2%.

What is Everest Re Group, Ltd.'s operating profit margin?

Everest Re Group, Ltd. (EG) reported an operating income of $1.95B, resulting in an operating profit margin of 11.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Everest Re Group, Ltd.'s gross profit and gross margin?

Everest Re Group, Ltd. (EG) generated $3.55B in gross profit for the year, representing a gross profit margin of 20.5%. This demonstrates the company's core pricing power and production efficiency.